Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : APRINOIA is developing an antibody platform, with APNmAb005 being a novel monoclonal antibody with greater selectivity for pathologic forms of tau that contribute to the pathogenesis of AD and primary tauopathies for the treatment of neurodegenerative di...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
August 23, 2023
[18F]APN-1607 PET in Subjects With AD Compared to HC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
September 16, 2022
A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The candidate was selected from APRINOIA’s proprietary antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
October 28, 2019